生物活性

• 描述Demeclocycline HCl is a tetracycline antibiotic; is an antibiotic in the treatment of Lyme disease, acne, and bronchitis. Demeclocycline caused a dose-dependent decrease in IOP (intraocular pressure). The maximum IOP decrease of approximately 12 mm Hg occurred 5 days after intravitreal administration of 0.5 mg, with the effect persisting for over a week. Demeclocycline did not alter tonographically measured aqueous humor outflow facility or episcleral venous pressure. Intravitreal demeclocycline similarly lowered IOP in cats, with the duration of effect lasting up to 20 days^[3]. Demeclocycline appears therefore to be an effective maintenance treatment of SIADH (inappropriate secretion of antidiuretic hormone), and the azotaemia that occurs is reversible and probably dose dependent^[4]. Perioperative administration of demeclocycline reliably inhibits the effects of increased VP (vasopressin) secretion commonly seen in patients undergoing CABG (coronary artery bypass grafting) procedures^[5]. Moreover, demeclocycline hydrochloride (1,200 mg/day) induced production of hypotonic urine and corrected hyponatremia despite large fluid intakes^[6]. Demeclocycline (900 mg/day) can at least partially inhibit the action of ADH (inappropriate antidiuretic hormone) in the setting of tumor-induced ADH secretion, with the production of a reversible, partial nephrogenic diabetes insipidus, and with few or no side effects. Demeclocycline may be useful in the treatment of chronic inappropriate ADH secretion^[7].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... more >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Collapse <<
  NCT02771535	Unipolar Depression	Not Applicable	Completed	-	Germany ... more >> University Medical Center Hamburg Eppendorf Hamburg, Germany, 20246 Collapse <<
  NCT03268434	Unipolar Depression	Not Applicable	Recruiting	September 2019	Germany ... more >> Asklepios Klinik Nord-Ochsenzoll Recruiting Hamburg, Germany, 22419 Contact: Marion Hagemann-Goebel, Dr. Collapse <<

• 更多
• 参考文献

• [1] Cottone JA, Langlais RP. Recurrent aphthous stomatitis-literature review. Report of three cases treated with demeclocycline hydrochloride. J Oral Med. 1977 Jan-Mar;32(1):21-4.

  [2] Mendoza GB Jr, Gerwig WH Jr, et al. Prophylactic use of antibacterial drugs following cystoscopy: a double-blind controlled study of demeclocycline hydrochloride and sulfamethoxypyridazine. J Urol. 1971 Nov;106(5):682-4.

  [3] Wallace I, Krupin T, Stone RA, Moolchandani J. The ocular hypotensive effects of demeclocycline, tetracycline and other tetracycline derivatives. Invest Ophthalmol Vis Sci. 1989;30(7):1594‐1598

  [4] Perks WH, Walters EH, Tams IP, Prowse K. Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone. Thorax. 1979;34(3):324‐327

  [5] Horattas MC, Evasovich MR, Muakkassa FF, Hopkins S, Kamienski P. Perioperative vasopressin secretion treated by demeclocycline. Am Surg. 1998;64(3):281‐286

  [6] De Troyer A. Demeclocycline. Treatment for syndrome of inappropriate antidiuretic hormone secretion. JAMA. 1977;237(25):2723‐2726

  [7] Cherrill DA, Stote RM, Birge JR, Singer I. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med. 1975;83(5):654‐656

• 更多

• Collapse